Skip to main content

Core value dossiers for medical technologies

Essential tool to support market access and marketing efforts through the lifecycle of the product

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

The 2025 Work Programme for the new joint EU-level HTA framework (HTAR) released

On December 3, 2024, the Member State Coordination Group on HTA released the 2025 Annual Work Programme for the new joint EU-level HTA framework (Regulation on Health Technology Assessment, HTAR). The framework will be fully operational from January 12, 2025.

The EU Regulation on Health Technology Assessment (2021/2282) came into force on January 11, 2022. During the preparatory phase for HTAR implementation, the Coordination Group on HTA (HTACG) was established, consisting of representatives from Member States, primarily from HTA authorities and bodies. The HTACG’s main responsibilities include coordinating and adopting joint HTA work conducted by its sub-groups within the HTAR framework.

For medical devices, the following sub-groups have been established:

  • Joint Clinical Assessments (JCA);
  • Joint Scientific Consultations (JSC);
  • Identification of Emerging Health Technologies (EHT);
  • Development of Methodological and Procedural Guidance.

The 2025 Work Programme outlines these plans related to medical devices:

  • Joint work on medical devices will begin with joint scientific consultations (JSCs);
  • Medical device manufacturers will be invited to submit JSC requests in the second half of 2025;
  • The HTACG plans to initiate 1–3 JSCs for medical devices in 2025, with a gradual increase in offerings in subsequent years;
  • No joint clinical assessments (JCAs) for medical devices will be conducted in 2025. The HTACG will focus on collaborating with Member States to develop JCA procedures for medical devices.

Detailed instructions for submitting JSC requests via the HTA IT Platform will be published by the HTA Secretariat in due course.

See more details here and here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.